Recently, the somatostatin receptor subtype 2 (SSTR2) selective antagonist sst 2 -ANT was determined to have a high affinity for SSTR2. Additionally, 111 In-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-sst 2 -ANT showed high uptake in an SSTR2-transfected, tumor-bearing mouse model and suggested that radiolabeled SSTR2 antagonists may be superior to agonists for imaging SSTR2-positive tumors. This report describes the synthesis and evaluation of 64 Cu-CB-4,11-bis(carboxymethyl)-1, 4,8,11-tetraazabicyclo[6.6.2]hexadecane-sst 2 -ANT ( 64 Cu-CB-TE2A-sst 2 -ANT) as a PET radiopharmaceutical for the in vivo imaging of SSTR2-positive tumors. Methods: Receptor-binding studies were performed to determine the dissociation constant of the radiopharmaceutical 64 Cu-CB-TE2A-sst 2 -ANT using AR42J rat pancreatic tumor cell membranes. The internalization of 64 Cu-CB-TE2A-sst 2 -ANT was compared with that of the 64 Cu-labeled agonist 64 Cu-CB-TE2A-tyrosine 3 -octreotate ( 64 Cu-CB-TE2A-Y3-TATE) in AR42J cells. Both radiopharmaceuticals were also compared in vivo through biodistribution studies using healthy rats bearing AR42J tumors, and smallanimal PET/CT of 64 Cu-CB-TE2A-sst 2 -ANT was performed. Results: The dissociation constant value for the radiopharmaceutical was determined to be 26 6 2.4 nM, and the maximum number of binding sites was 23,000 fmol/mg. 64 Cu-CB-TE2A-sst 2 -ANT showed significantly less internalization than did 64 Cu-CB-TE2A-Y3-TATE at time points from 15 min to 4 h. Biodistribution studies revealed that the clearance of 64 Cu-CB-TE2A-sst 2 -ANT from the blood was rapid, whereas the clearance of 64 Cu-CB-TE2A-sst 2 -ANT from the liver and kidneys was more modest at all time points. Tumor-to-blood and tumor-to-muscle ratios were determined to be better for 64 Cu-CB-TE2A-sst 2 -ANT than those for 64 Cu-CB-TE2A-Y3-TATE at the later time points, although liver and kidney uptake was significantly higher. Small-animal imaging using 64 Cu-CB-TE2A-sst 2 -ANT revealed excellent tumor-to-background contrast at 4 h after injection, and standardized uptake values remained high even after 24 h. Conclusion: The PET radiopharmaceutical 64 Cu-CB-TE2A-sst 2 -ANT is an attractive agent, worthy of future study as a PET radiopharmaceutical for the imaging of somatostatin receptorpositive tumors.
Radi olabeled somatostatin analogs have become important agents for molecular imaging and targeted radiotherapy of somatostatin receptor-positive tumors. Somatostatin analogs such as octreotide, octreotate, and tyrosine 3 -octreotate (Y3-TATE) have been radiolabeled with 18 F and 124 I directly or conjugated to a bifunctional chelator for radiolabeling with metal radionuclides (1) (2) (3) . Moreover, they have also been modified at the carboxy and amino termini to create multimodal imaging agents that can be used for PET, SPECT, and planar optical imaging (4) .
Recently, Ginj et al. compared somatostatin receptor agonists and antagonists as targeting ligands and their specific affinity for the 5 different subtypes of the somatostatin receptor (5) . The somatostatin receptor subtype 2 (SSTR2) selective antagonist sst 2 -ANTwas determined to have a high affinity for the SSTR2 receptor, which was not decreased by the presence of the conjugated chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) or a conjugated nat In-DOTA complex. Internalization of the SSTR2 was not observed using immunofluorescence internalization assays, even when the concentration of the antagonist exceeded 9 mM. Biodistribution studies using 111 In-DOTA-sst 2 -ANT revealed high uptake and a slow clearance of the radiopharmaceutical in nude mice bearing tumors comprising human embryonic kidney (HEK) cells that were stably transfected to express only SSTR2.
Although 111 In-DOTA-sst 2 -ANT shows promise as a radiotracer for SPECT, DOTA-sst 2 -ANT has not been evaluated as a PET radiopharmaceutical labeled with other M 21 or M 31 radiometals such as 64 Cu, 68 Ga, or 86 Y. In the case of 64 Cu, the imaging properties are expected to be suboptimal because of the reputation of DOTA as an indiscriminate metal chelator and the kinetic lability of the radiometal complexes (6) . Although the latter factor contributes to greater radiometal transchelation to cellular proteins, both factors have been shown to reduce image quality and adversely affect the imaging results.
Over the last decade, Weisman and Wong and others have synthesized and studied several new bridged tetraazamacrocyclic chelators and their transition metal complexes (7, 8) . These ligands use an ethylene bridge between nonadjacent nitrogens located on the tetraazamacrocycle and have been synthesized with carboxymethyl arms to fully envelop the cation in an octahedral geometry and neutralize the dicationic charge of the metal center. In addition, several reports exist that demonstrate superior stability of these 64 Cu complexes in vivo when compared with 64 Cu complexes formed with traditional chelators such as DOTA and 1,4,8,11-tetraazacyclo-dodecane-1,4,8,11-tetraacetic acid (9) . This enhanced stability was retained even after conjugation to the peptide Y3-TATE (10) . This study sought to combine the enhanced binding properties of the sst 2 -ANT peptide with the ultrastable 64 Cu chelator 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A) ( Fig. 1 ) to determine its usefulness as a PET radiopharmaceutical for the in vivo imaging of SSTR2-positive tumors.
MATERIALS AND METHODS
64 Cu (half-life, 12.7 h; b 1 , 17.8%, E b1max , 656 keV; b 2 , 38.4%, E b2max , 573 keV) (11) was produced on a CS-15 biomedical cyclotron at Washington University School of Medicine (12) . All other chemicals were purchased from Sigma-Aldrich Chemical Co., and solutions were prepared using ultrapure water (resistivity, 18 MV cm). The peptide Y3-TATE was prepared by standard literature protocols (13) , and CB-TE2A and 64 Cu-CB-TE2A-Y3-TATE were prepared according to literature procedures (8, 10) . Radiochemistry reaction progress and purity were monitored by analytic reversed-phase high-performance liquid chromatography (HPLC), which was performed on a chromatography system (600E; Waters) with a photodiode array detector (991; Waters) and a radioactivity detector (Ortec, model 661; EG&G Instruments). A C-18 column (Vydak) was used with a gradient that changed from 0.1% trifluoroacetic acid (TFA) in water to a concentration of 60:40 0.1% TFA/Water:0.1% TFA/CH 3 CN over the course of 15 min. In addition, radio-thin-layer chromatography (radio-TLC) was conducted on an AR scanner (Bioscan) equipped with a concentration of 10% methane:argon gas supply and a PC interface running analysis software (Winscan, version 3; Academic Software). C-18 plates with an eluent mixture of 3:7 10% NH 4 OAc:MeOH and the complex 64 Cu(OAc) 2 as a standard control were used. Radioactive samples were counted using an automated well-type g-counter (8000; Beckman) or a b-plate reader (1450 Micro Beta; Perkin Elmer). The PET data were acquired using either a microPET Focus 120 or a microPET Focus 220 (Siemens Medical Solutions), and the CT data were collected using a microCAT II (Siemens Medical Solutions).
Male Lewis rats (age, 21 d; weight, 40-50 g) were purchased from Charles River Laboratories and handled according to the procedures outlined by the Washington University Animal Studies Committee. AR42J pancreatic tumors were implanted into the hind limbs by serial passage as previously described and were allowed to grow 10-14 d, after which time tumors achieved a solid palpable mass (10) .
Synthesis of CB-TE2A-sst 2 -ANT
The peptide CB-TE2A-Phe(4-NO 2 )-cyclo(D-Cys-Tyr-D-TrpLys-Thr-Cys)-DTyr-NH 2 was synthesized on a 30 mM scale by standard Fmoc solid-phase peptide synthesis, as reported previously (14) . The peptide was assembled on a Rink Amide resin starting with Fmoc-D-Tyr. The coupling of subsequent Fmocprotected amino acids (90 mmol each) was achieved by activating the carboxyl group with a 1:1 mixture of N-hydroxylbenzotriazole (90 mmol) and 2-( 1 H benzotriazole-1-yl)-1,1,1,3-tetramethyluronium hexafluorophosphate (90 mmol) and N,N-diisopropylethylamine (DIEA; 180 mmol). Disulfide cyclization was achieved with thallium trifluoroacetate (27.6 mg, 50.4 mmol) in anhydrous dimethylformamide (1 mL), and CB-TE2A (90 mmol) was incorporated at the N-terminus of the peptide by activating the acid with dicyclohexylcarbodiimide (120 mmol) and DIEA (120 mmol). Cleavage of the peptide from resin and HPLC purification were performed as described previously (14) . HPLC purification was performed on a protein and peptide C-18 column (22 · 250 mm, 5 mm; Vydac) at a flow rate of 10 mL/min. Flow A was 0.1% TFA in water, and flow B was 0.1% TFA in acetonitrile. The elution method for purification started with a linear gradient from 90% to 70% A over 10 min, followed by 70% to 50% A for 10 min, and then from 50% to 35% A for 10 min. The elution profile was monitored by ultraviolet absorbance at 214 nm.
The CB-TE2A-sst 2 -ANT was obtained as a white powder (12 mg, 8 mmol) after lyophilization in a 3:1 H 2 O:acetonitrile mixture. Analytic HPLC was performed on a Vydac protein and peptide C-18 column (100 · 4.6 mm, 5 mm) at a flow rate of 1 mL/ min. Flow A was 0.1% TFA in water, and flow B was 0.1% TFA in acetonitrile. The elution method for analytic HPLC started with a linear gradient from 90% to 40% A over 5 min, followed by 40% to 25% A for 2 min, and the elution profile was monitored by ultraviolet absorbance at 214 nm. The peptide was also characterized by electrospray mass spectrometry. Calculated mass, 1,479.0; (ESI1MS) m/z (% relative intensity, ion), 1,479.80 (5, M11), 740.20 (100, M12).
A similar procedure was used to prepare and purify the control peptide AC-Phe(4-NO 2 )-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)-DTyr-NH 2 (10 mg, 7 mmol), except that acetic anhydride was used to cap the N-terminal amino group. HPLC purification was performed as described above. The elution method for purification started with a linear gradient from 90% to 75% A over 10 min, followed by 75% to 65% A for 15 min, and then 65% to 55% A for 10 min; the elution profile was monitored by ultraviolet absorbance at 214 nm. Analytic HPLC was performed as previously described, and electrospray mass spectrometry also was performed. Calculated mass, 1,197.60; (ESI1MS) m/z (% relative intensity, ion), 1, 196 .85 (100, M11).
Radiochemistry
The complexation of 64 Cu to CB-TE2A-sst 2 -ANT was achieved by reacting 1 mg (6.3 · 10 24 mmol) of CB-TE2A-sst 2 -ANT, 118 mL of 0.1 M NH 4 OAc (pH, 8.0), and 37 MBq of 64 CuCl 2 in 0.1N hydrochloric acid for 1.5 h at 95°C. The reaction was further purified using a previously published method (15) . Purity after purification was greater than 95% based on radio-TLC and radio-HPLC analysis.
Receptor-Binding Studies
AR42J cell membrane preparations were used for binding assays, and assays were performed on a 96-well filtration plate (Multiscreen Durapore; Millipore) using previously described methods, with some modifications (16) . Membranes were diluted in binding buffer (50 mM Tris-hydrochloride [pH, 7.4]; 5 mM MgCl 2 Á 6 H 2 O; 0.1% bovine serum albumin; and 0.5 mg of aprotinin, 200 mg of bacitracin, 10 mg of leupeptin, and 10 mg of pepstatin A per milliliter), and 20 mg of membrane protein were used per well. Increasing concentrations of 64 Cu-CB-TE2A-sst 2 -ANT were added to membranes to measure total binding, and unspecific binding was determined by conducting the assay in the presence of an excess of CB-TE2A-sst 2 -ANT. After incubation of the membranes at room temperature for 2 h, the medium was removed and the membranes were washed twice with 200 mL of binding buffer. OptiPhase Super-Mix (50 mL; PerkinElmer) was added to each well, and bound activity was measured with a liquid scintillation and luminescence counter (1450 Microbeta; Perkin Elmer). All dissociation constant (K d ) values were estimated from nonlinear curve fitting of bound peptide versus the sum of the concentrations of 64 Cu-and CB-TE2A-sst 2 -ANT using software (Prism; GraphPad).
Internalization Studies
AR42J cells were cultured in Iscove's Dulbecco/Vogt modified Eagle's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum; cells were incubated at 37°C in a humidified 5% CO 2 atmosphere. Before each assay, cells were harvested with a rubber-tipped scraper (Sarstedt, Inc.), washed twice with phosphate-buffered saline, and resuspended in Iscove's DMEM supplemented with 10% fetal bovine serum at 1 · 10 6 cells per 500 mL. Aliquots of cell suspension (500 mL) were placed in 1.7-mL microfuge tubes (Midwest Scientific). 64 Cu-CB-TE2A-sst 2 -ANT (specific activity, 8.5 MBq/mg) or 64 Cu-CB-TE2A-Y3-TATE (specific activity, 8.5 MBq/mg) was added to each tube, to a final concentration of 4.0 nM for each radiotracer. The tubes were incubated at 37°C, with rotation. To block specific binding at each time point, tubes containing 500-mL cell suspensions (1 · 10 6 cells/500 mL) were incubated 5 min at room temperature with 2 mg of Y3-TATE or 2 mg of sst 2 -ANT. At each time point, surface-bound fractions were collected as previously described (17) . Internalized radioactivity was collected by lysing the cells in 0.5% sodium dodecyl sulfate. Total protein concentration in the cell lysate was determined using the BCA Protein Assay (Pierce Biotechnology). Internalized and surface-bound fractions were expressed as counts/min/mg of protein.
Biodistribution
The biodistribution study was conducted as previously described (18) . Briefly, healthy male Lewis rats (39 d old) bearing AR42J tumors were injected with 64 Cu-CB-TE2A-sst 2 -ANT (0.74 MBq, 40 ng in 150 mL/rat) or 64 Cu-CB-TE2A-Y3-TATE (0.74 MBq, 25 ng in 150 mL/rat) via the tail vein. Animals were sacrificed at selected time points after injection, and organs of interest were removed, weighed, and counted on a g-counter (8000; Beckman). Blocking studies were also performed using healthy male Lewis rats (39 d old) bearing AR42J tumors to examine in vivo uptake specificity. 64 Cu-CB-TE2A-sst 2 -ANT (0.74 MBq, 40 ng in 150 mL/rat) was coinjected with 175 mg of sst 2 -ANT via the tail vein, or 64 Cu-CB-TE2A-Y3-TATE (0.74 MBq, 25 ng in 150 mL/rat) was coinjected with 175 mg of Y3-TATE via the tail vein. The percentage injected dose per gram and percentage injected dose per organ were calculated by comparing them with a weighed, counted standard.
Imaging Using Small-Animal PET/CT
Imaging studies were performed with male Lewis rats bearing AR42J tumors in both hind limbs. Four rats were injected with 64 Cu-CB-TE2A-sst 2 -ANT (13 MBq, 740 ng in 150 mL/rat). At 1, 4, and 24 h after injection, rats were anesthetized with 1-2% isoflurane and imaged. Blocking studies were also performed at 4 h. A separate set of 4 male Lewis rats bearing AR42J tumors in their hind limbs were coinjected via the tail vein with 64 Cu-CB-TE2A-sst 2 -ANT (9.8 MBq, 550 ng in 150 mL/rat) and 1,000 mg of sst 2 -ANT. For both groups and at all time points, standardized uptake values (SUVs) were determined using the formula SUV 5
Statistical Methods
All of the data are presented as mean 6 SD or mean followed by 95% confidence interval (CI) in parentheses. For statistical classification, a Student t test (2-tailed, unpaired) was performed using Prism software (GraphPad). Any P value less than 0.05 was considered significant.
RESULTS

Synthesis of Peptides and CB-TE2A Conjugate
All peptides used in this study were prepared by standard Fmoc peptide chemistry. Disulphide cyclization and peptide purification were performed as reported elsewhere (14) . Pretreatment of CB-TE2A with dicyclohexylcarbodiimide appears to form an acid anhydride from the dicarboxylic acid function, which then reacts selectively with the N-terminal amino group of the peptide on solid support. The desired compound was obtained in 26% yield, and the presence of a cross-linked peptide was not observed, demonstrating the advantage of the solid-phase synthesis approach over reactions in solution. Previous studies have shown that a similar chelating group that possesses 2 reactive carboxylic acid groups (tri-t-butyl-diethylenetriaminepentaacetic acid [DTPA]) forms predominantly a monopeptide conjugate on solid support (13) . The excellent stability of CB-TE2A under the TFA peptide cleavage condition facilitates the automation of the synthesis protocol.
Radiochemistry
The preparation of 64 Cu-CB-TE2A-sst 2 -ANT was performed using a previously described method (15) . Radiochemical purity was between 60% and 99% after the reaction was heated. In those reactions of the highest purity ($95%), only 1 peak (R f of 0.6) was observed by radio-TLC, which was attributed to the expected radiopharmaceutical product. This result was validated using radio-HPLC, in which only 1 product peak was observed with a retention time of 15.5 6 0.5 min. The presence of 64 Cu(OAc) 2 at the origin (R f 5 0) of the TLC plate or in void volume of the HPLC run (retention time 5 1-2 min) was negligible, indicating that nonchelated 64 Cu was not present in the reaction and the formation of the complex was complete.
For reactions of less than 95% purity due to nonchelated 64 Cu, the reaction was purified using ethylenediaminetetraacetic acid (EDTA) and a C-18 SepPak Light cartridge (Waters). A buffered EDTA solution was added to chelate any 64 Cu not already incorporated into the ligand. A total of 75% of the radiolabeled product was eluted from the cartridge using absolute ethanol containing 0.5% acetic acid. Concentration using a vacuum concentrator did not cause significant degradation to the radiopharmaceutical, and after redilution in a suitable buffer or saline the radiopharmaceutical demonstrated sufficient purity to be used for further studies with cells and animals. 64 Cu-CB-TE2A-sst 2 -ANT was obtained at a purity of greater than 95% and a specific activity range of 13-37 MBq/mg using this method.
Receptor-Binding and Cellular Internalization Studies
A saturation binding assay was performed with AR42J tumor cell membranes bearing SST receptors, using previously described procedures that were slightly modified ( Fig. 2) 64 Cu-CB-TE2A-sst 2 -ANT had a significantly lower affinity for SSTR2 than was observed for 64 Cu-CB-TE2A-Y3-TATE (K d , 1.7 nM). However, 64 Cu-CB-TE2A-sst 2 -ANT binds to 14-fold more SSTR sites than does the agonist (B max for the agonist vs. antagonist, 1,596 fmol/mg vs. 23,000 fmol/mg) on the tumor cell membrane.
Internalization studies were also performed using AR42J tumor cells (Fig. 3) . The nonzero y-intercept for both the agonist and antagonist suggests a rapid early internalization phase at 15 min, followed by a slower phase at 30 min. Data after 30 min showed no significant change in radiotracer internalization. Although it was expected that there would be either minimal or no internalization of 64 Cu-CB-TE2A-sst 2 -ANT, there were significant levels of internalized agent (10-fold less at 15 and 30 min for 64 Cu-CB-TE2A-sst 2 -ANT than for 64 Cu-CB-TE2A-Y3-TATE, however). In both cases, addition of the cold peptides (sst 2 -ANT or Y3-TATE), along with the respective radiotracer to the cell suspensions, inhibited the internalization of either radiopharmaceutical. The surface-bound fraction of 64 Cu-CB-TE2A-sst 2 -ANT was significantly greater than that of 64 Cu-CB-TE2A-Y3-TATE between 30 and 240 min.
Biodistribution Studies
Biodistribution studies of 64 Cu-CB-sst 2 -ANT and 64 Cu-CB-TE2A-Y3-TATE were conducted on 39-d-old AR42J tumor-bearing male Lewis rats. The results of those studies are depicted in Figure 4 . 64 Cu-CB-TE2A-Y3-TATE showed rapid blood clearance at 1 h, and by 24 h 74% of the activity present at 1 h was removed from the blood (Supplemental Table 1 ; supplemental materials are available online only at FIGURE 2. In vitro binding affinity of 64 Cu-CB-TE2A-sst 2 -ANT for SSTR harvested from AR42J rat pancreatic tumor cell membranes was determined using saturation binding assay. K d of radiopharmaceutical was determined to be 26 6 2.4 nM, and B max was determined to be 23,000 fmol/mg. http://jnm.snmjournals.org). In contrast, activity remained higher in the liver and kidneys, with slower clearance occurring from these tissues over time. From 1 to 24 h, activity in the liver fell by 35%, whereas 50% of the 1-h activity was excreted from the kidneys by 24 h. The amount of activity associated with SSTR-expressing tissues and AR42J tumors was also determined. Initial uptake in the tumor was modest when compared with the tracer uptake in the adrenals and pituitary gland. Over time, slow clearance from these tissues was also observed, with only 52% of the 1-h activity excreted from the adrenals at 24 h, whereas 60% and 69% of the 1-h activity had been cleared from the pituitary and tumor, respectively. This yielded tumor-to-blood ratios of 17, 42, and 20 at 1, 4, and 24 h, respectively, and tumor-to-muscle ratios of 40, 76, and 47 at 1, 4, and 24 h, respectively. 64 Cu-CB-TE2A-sst 2 -ANT also demonstrated rapid blood clearance, and by 24 h after injection 95% of the 1-h activity had been filtered from the blood (Supplemental Table 2 ). However, unlike the former tracer, activity levels in the liver actually increased by 2% from the 1-h time point, whereas only 16% of the 1-h activity localized in the kidney was excreted by 24 h. Activity levels in SSTR-positive tissues and tumor were high, but clearance from these tissues was efficient, with 93% and 92% of the 1-h activity localized in the adrenal and pituitary glands excreted by 24 h, respectively. Finally, tumor uptake for this radiopharmaceutical was less than for the analogous 64 Cu-labeled agonist; however, clearance was slow, with only 50% of the 1-h activity being removed by 24 h. Tumor-to-blood ratios were 7, 35, and 72 at 1, 4, and 24 h, respectively, and tumor-to-muscle ratios were 17, 70, and 93 at 1, 4, and 24 h, respectively. Although the tumor uptake was lower for 64 Cu-CB-TE2A-sst 2 -ANT, the tumor-to-background ratios were significantly higher than those of 64 Cu-CB-TE2A-Y3-TATE at 24 h (tumor-to-blood P , 0.0001; tumor-to-muscle P , 0.0006).
Blocking studies were performed at 4 h after injection for both radiotracers by coinjecting the cold peptide Y3-TATE or sst 2 -ANT with its respective radiopharmaceutical (Fig.  5) . Injection of Y3-TATE effectively blocked the binding of 64 Cu-CB-TE2A-Y3-TATE to the tumor by 75%, and coinjection of sst 2 -ANT decreased the binding of 64 Cu-CB-TE2A-sst 2 -ANT to AR42J tumors by 74%. This blocking resulted in 4-h tumor-to-blood and tumor-to-muscle ratios for 64 Cu-CB-TE2A-sst 2 -ANT of 6 and 13, respectively. In addition, coinjection of the respective agonist or antagonist blockades also decreased the amount of activity observed in somatostatin-positive normal tissues. For example, coinjection of Y3-TATE with 64 Cu-CB-TE2A-Y3-TATE decreased the amount of activity observed in the pituitary and adrenal glands by 96% and 97%, respectively, whereas coadministration of sst 2 -ANT with 64 Cu-CB-TE2A-sst 2 -ANT blocked 70% and 86% of the activity in the pituitary and adrenal glands, respectively. However, tissues that were not SSTRpositive did not demonstrate reduced binding of the tracer.
In Vivo Small-Animal PET Imaging Figure 6 represents the results of small-animal PET/CT imaging experiments performed on male Lewis rats bearing AR42J tumors in their hind limbs. Excellent tumor-tobackground contrast is observed at 4 h after injection using 64 Cu-CB-TE2A-sst 2 -ANT, with an average tumor SUV (n 5 8) of 2.45 6 0.5 and an SUV tumor-to-muscle ratio of 58. SUVs remained high even after 24 h, with the average tumor SUV (n 5 6) decreasing by only 56% to 1.11 6 0.24 and yielding an SUV tumor-to-muscle ratio of 37. These ratios are far better than those observed for 64 Cu-CB-TE2A-Y3-TATE, which had 4-and 24-h SUV tumor-to-muscle ratios of only 5 and 7, respectively (10) . The effects of the administered blockade were also evident at 4 h. The average tumor SUV (n 5 8) was calculated to be 0.62 6 0.13, and the tumor-to-muscle ratio was calculated to be 10. Based on SUV analysis, 75% of the tumor-associated activity was effectively blocked when excess sst 2 -ANT was coinjected with the radiopharmaceutical, correlating well with the results of blocking studies performed during biodistribution experiments. (5). Because of the impressive biodistribution of the 111 In-labeled sst 2 -ANT, and the advantages of PET over SPECT in sensitivity and resolution, the goal of this work was to prepare a peptide-chelator conjugate using the peptide sst 2 -ANT and the chelator CB-TE2A, label the conjugate with 64 Cu, and evaluate it as a PET radiopharmaceutical. 64 Cu was chosen as the PET isotope because of its favorable decay characteristics (half-life, 12.7 h; b 1 , 17.8%, E b1 max , 656 keV; b 2 , 38.4%, E b2max , 573 keV), which make it useful for imaging and radiotherapy. The chelator CB-TE2A was chosen because of its ability to form ultrastable 64 Cu metal complexes. We chose to evaluate 64 Cu-CB-TE2A-sst 2 -ANT in the AR42J model, because it is a model used to evaluate several radiometal-labeled somatostatin analogs (10, 19) . 64 Cu-CB-TE2A-sst 2 -ANT demonstrated a K d of 26 nM and a B max of 23,000 fmol/mg for the SSTR2 with AR42J rat pancreatic carcinoma cell membranes. These values stand in contrast to those determined for 64 Cu-CB-TE2A-Y3-TATE, which should function as an agonist for the SSTR2. Under similar experimental conditions, 64 Cu-CB-TE2A-Y3-TATE demonstrated a K d of 1.5 nM and a B max of 1,551 fmol/mg (10). These results suggest that although the sst 2 -ANT peptide does not have as high a binding affinity for the SSTR2 receptor, it is able to label approximately 14-fold more sites on the membrane than the Y3-TATE compound and is in agreement with what Ginj et al. observed in comparing 111 In-DOTA-sst 2 -ANT with the agonist 111 In-DTPA-TATE (5). This increase in B max may be attributed to the ability of the antagonist to interact and bind to a larger number of SSTR2 conformations and possibly its stabilization in the lipid-rich environment of the receptor (5). Although AR42J tumor cells have also been shown to express SSTR1, SSTR3, and SSTR5, the affinity of these receptor subtypes for sst 2 -ANT is 100 times lower than its affinity for SSTR2 (20) , suggesting that binding to other subtypes does not significantly interfere with these binding results.
Assays were performed to determine the extent of radiopharmaceutical internalization induced when 64 Cu-CB-TE2A-sst 2 -ANT was incubated with AR42J cells and data were compared with the radiolabeled agonist 64 Cu-CB-TE2A-Y3-TATE. Rapid internalization of 64 Cu-CB-TE2A-Y3-TATE by AR42J tumor cells was observed between 15 and 30 min. This rapid internalization is followed by a slow rise in the amount of activity internalized after 30 min, suggesting that after 30 min have elapsed, receptor saturation has been achieved. At 30 min, it is likely that receptors that have bound the radiopharmaceutical have been internalized, and few receptors are available on the cell surface to bind more of the radiopharmaceutical, which may explain why internalization after 30 min remains a relatively static process. Internalization of 64 Cu-CB-TE2A-Y3-TATE was blocked with excess Y3-TATE, demonstrating this to be a receptor-mediated process. Much lower, yet significant, levels of internalization were observed for 64 Cu-CB-TE2A-sst 2 -ANT. Similar to 64 Cu-CB-TE2A-Y3-TATE, internalization of 64 Cu-CB-TE2A-sst 2 -ANT occurred rapidly until 30 min but slowed after this time point. Cell surface-associated activity was greater for 64 Cu-CB-TE2A-sst 2 -ANT than for 64 Cu-CB-TE2A-Y3-TATE after 30 min, suggesting that internalization occurs less rapidly for the former and may reflect the labeling of an increased number of binding sites on the cell surface.
These observations stand in contrast to what has been previously reported, as Ginj et al. showed no observable internalization of the sst 2 -ANT peptide receptor complex when immunofluorescence microscopy was used to study the effect of agonists and antagonists on HEK229 cells, which were stably transfected to express SSTR2 (5). Reubi et al. have demonstrated that relatively small changes in a radiolabeled peptide, such as changing the chelator, can markedly change the SSTR binding profile of the somatostatin analogs (21) . These small changes may have proven sufficient to alter the characteristics of the peptide and may explain why low yet significant levels of internalization of 64 Cu-CB-TE2A-sst 2 -ANT are observed. In addition, previously reported analyses used fluorescence microscopy to determine the extent of receptor internalization. Although providing valuable information, fluorescence microscopy remains a qualitative assay when compared with assays with radiolabeled compounds (22) . Finally, because this work was concerned with the internalization of the radiopharmaceutical and not merely the receptor, membrane remodeling must also be considered. The plasma membrane of a eukaryotic cell is a dynamic structure, and substantial amounts of the plasma membrane are being continually recycled (23) . This recycling allows membrane components and those ligands associated either specifically or nonspecifically with the membrane to be brought into the interior of the cell through mechanisms other than receptor-mediated endocytosis.
Comparative in vivo studies of 64 Cu-CB-TE2A-sst 2 -ANT and 64 Cu-CB-TE2A-Y3-TATE were performed. Although the biodistribution of 64 Cu-CB-TE2A-Y3-TATE has been determined previously, it was reevaluated for a more accurate comparison with 64 Cu-CB-TE2A-sst 2 -ANT. In the previous study, 2-fold more activity and 3-fold more mass were injected per animal than in the current study (10) , possibly giving rise to higher uptake in the AR42J tumors (24) .
Both radiopharmaceuticals demonstrated rapid blood clearance at all time points, indicating that this tracer is stable after injection, but liver and kidney clearance were more modest over time. This slower clearance in the liver can be attributed to a main excretion route, and uptake and clearance in the kidneys are slower because of an expected 11 charge on the radiopharmaceutical. Several reports have been published describing the effect of radiopharmaceutical charge on kidney uptake. Studies using 111 In-DTPA-conjugated peptides demonstrated that renal retention was highest for positively charged peptide conjugates, and similar charge effects were seen when 64 Cu-labeled azamacrocycles were studied (25, 26) . In addition, similar trends were also observed for 64 Cu-CB-TE2A-Y3-TATE when previously evaluated (10) . Both radiotracers also demonstrated substantial uptake in SSTR-positive tissues and AR42J tumors, which was reduced on the coinjection of blockade, indicating that interaction between the radiopharmaceuticals and the tissues is a receptor-mediated process. Although 64 Cu-CB-TE2A-sst 2 -ANT demonstrated lower uptake in SSTR-positive tissues and tumor than did 64 Cu-CB-TE2A-Y3-TATE, 64 Cu-CB-TE2A-sst 2 -ANT demonstrated higher tumor-toblood and tumor-to-muscle ratios at the latest time point of 24 h. These results may be a reflection of the increased chemical stability and increased hydrophobicity of the antagonist, which results in a longer duration of action and possible stabilization in the lipid-rich environment of the receptors (5). In addition, rebinding of 64 Cu-CB-TE2A-sst 2 -ANT after dissociation from the receptor also may explain these higher ratios and the superior tumor-to-background contrast observed in small-animal imaging experiments (27) . This observation suggests that 64 Cu-CB-TE2A-sst 2 -ANT, compared with 64 Cu-CB-TE2A-Y3-TATE, seems to remain bound to the tumor tissue for an increased length of time and provides insight into the promise of 64 Cu-CB-TE2A-sst 2 -ANT as a PET agent.
The relative tumor uptake observed in our experiments is much lower than what was reported by Ginj et al. with HEK229 cells that were stably transfected to express SSTR2 and 111 In-DOTA-sst 2 -ANT (5). In this study, the rat pancreatic carcinoma cell line AR42J reflects a tumor cell line with a natural expression of SSTR2 and other somatostatin subtypes (20) . Hence, the concentration of SSTR2 in AR42J cells is lower than the SSTR2 number on the engineered HEK229 cells, accounting for the discrepancy in the biodistribution results of the 2 reports (5). Moreover, somatostatin receptor number on normal SSTRpositive tissues has been observed to be species-dependant, possibly explaining differences in radiopharmaceutical uptake between this report and the report published by Ginj et al. For example, Ludvigsen et al. observed higher SSTR2 expression in the pancreas of mice than in the pancreas of normal rats (28) . Questions arise as to whether these results observed by Ginj et al. in a SSTR2-transfected cell line are an accurate reflection of the behavior of sst 2 -ANT in vivo, and the data presented here offer another perspective on imaging SSTR2 with radiolabeled antagonists. Despite the lower tumor uptake, small-animal imaging of AR42J tumors with 64 Cu-CB-TE2A-sst 2 -ANT produced images with good tumor-to-background contrast and high SUVs for target tissues (Fig. 6) . Both contrast and SUVs were decreased by the coadministration of blockade (sst 2 -ANT), demonstrating that binding of the radiopharmaceutical to the tumor in vivo is a receptor-mediated process and correlates with similar observations obtained through biodistribution studies.
CONCLUSION
The PET radiopharmaceutical 64 Cu-CB-TE2A-sst 2 -ANT has been evaluated in vitro using receptor binding and internalization assays and in vivo using biodistribution and small-animal imaging experiments with a natively SSTR2-expressing cell line, AR42J. Despite having a lower affinity for the SSTR2 receptor than the agonist 64 Cu-CB-TE2A-Y3-TATE and relatively modest tumor uptake, 64 Cu-CB-TE2A-sst 2 -ANT had superior tumor-to-background contrast, resulting in high tumor SUVs even after 24 h. 64 Cu-CB-TE2A-sst 2 -ANT is an attractive agent, worthy of future study as a PET radiopharmaceutical for the imaging of somatostatin receptor-positive tumors.
